1. Home
  2. NWGL vs BLRX Comparison

NWGL vs BLRX Comparison

Compare NWGL & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NWGL
  • BLRX
  • Stock Information
  • Founded
  • NWGL 2008
  • BLRX 2003
  • Country
  • NWGL Macau
  • BLRX Israel
  • Employees
  • NWGL N/A
  • BLRX N/A
  • Industry
  • NWGL
  • BLRX Biotechnology: Pharmaceutical Preparations
  • Sector
  • NWGL
  • BLRX Health Care
  • Exchange
  • NWGL Nasdaq
  • BLRX Nasdaq
  • Market Cap
  • NWGL 21.2M
  • BLRX 17.3M
  • IPO Year
  • NWGL 2023
  • BLRX 2011
  • Fundamental
  • Price
  • NWGL $1.36
  • BLRX $3.59
  • Analyst Decision
  • NWGL
  • BLRX Strong Buy
  • Analyst Count
  • NWGL 0
  • BLRX 2
  • Target Price
  • NWGL N/A
  • BLRX $220.00
  • AVG Volume (30 Days)
  • NWGL 5.5K
  • BLRX 154.8K
  • Earning Date
  • NWGL 11-29-2024
  • BLRX 03-25-2025
  • Dividend Yield
  • NWGL N/A
  • BLRX N/A
  • EPS Growth
  • NWGL N/A
  • BLRX N/A
  • EPS
  • NWGL N/A
  • BLRX N/A
  • Revenue
  • NWGL $21,707,613.00
  • BLRX $21,991,000.00
  • Revenue This Year
  • NWGL N/A
  • BLRX N/A
  • Revenue Next Year
  • NWGL N/A
  • BLRX N/A
  • P/E Ratio
  • NWGL N/A
  • BLRX N/A
  • Revenue Growth
  • NWGL N/A
  • BLRX N/A
  • 52 Week Low
  • NWGL $1.04
  • BLRX $3.20
  • 52 Week High
  • NWGL $21.97
  • BLRX $57.60
  • Technical
  • Relative Strength Index (RSI)
  • NWGL 50.42
  • BLRX 36.94
  • Support Level
  • NWGL $1.32
  • BLRX $3.26
  • Resistance Level
  • NWGL $1.59
  • BLRX $4.17
  • Average True Range (ATR)
  • NWGL 0.10
  • BLRX 0.28
  • MACD
  • NWGL -0.01
  • BLRX 0.24
  • Stochastic Oscillator
  • NWGL 40.74
  • BLRX 36.26

About NWGL Nature Wood Group Limited

Nature Wood Group Ltd is a vertically-integrated forestry company that focuses on FSC business operations. It produces various products, including logs, decking, flooring, sawn timber, recycled charcoal, synthesized charcoal, machine-made charcoal, and essential oils. The Group owns natural forest concessions and cutting rights for exploiting timbers on parcels of land in Peru. The Group is organized into two operating divisions; Direct Purchase and Original Design Manufacturer (ODM) Services, and Manufacturing segments. The Direct Purchase and ODM Segment that derives the majority of revenue engages in the business of sourcing live wood and owning designed designs on wood products for sales to end customers. Geographically, the company generates a majority of its revenue from China.

About BLRX BioLineRx Ltd.

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

Share on Social Networks: